38 results
Page 2 of 2
8-K
EX-99.1
9i6vrt rdq7oz3cr
26 Jul 21
Viridian Therapeutics Appoints Kristian Humer As Chief
7:35am
8-K
EX-1.1
yg0tdg ga4r
26 Apr 21
Entry into a Material Definitive Agreement
12:00am
S-8
j080chi
26 Mar 21
Registration of securities for employees
4:22pm
8-K
EX-2.1
saigg5uqay76
28 Oct 20
Acquisition includes clinical stage anti-IGF-1R monoclonal antibody, VRDN-001, intended for Company plans to use private placement financing proceeds of $91 million to advance multiple
9:28am
8-K
EX-99.1
9g6n54p6ws4of5gt
6 Aug 18
Entry into a Material Definitive Agreement
4:16pm
S-3
oqym5s sdm2j
10 Jul 15
Shelf registration
12:00am
10-K
9cijs77p twww3
27 Mar 15
Annual report
12:00am
424B4
qm8wqju
19 Feb 15
Prospectus supplement with pricing info
12:00am
FWP
lc25l08
2 Feb 15
Free writing prospectus
12:00am
FWP
smqc146
2 Feb 15
Free writing prospectus
12:00am
10-Q
ib856bj
14 Aug 14
Quarterly report
12:00am
424B4
79usdyhy3 cmlq
19 Jun 14
Prospectus supplement with pricing info
12:00am
DRS/A
iu81qf poleoiekhpjhl
30 Dec 13
Draft registration statement (amended)
12:00am